Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients

• Status: Unknown status
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The present study aims to investigate whether the dosage of the GnRH agonist used for triggering final oocyte maturation affects the maturity of the oocytes retrieved in high risk for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and recombinant FSH.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aristotle University Of Thessaloniki
• Collaborator: Eugonia IVF Unit, Athens, Greece
• Treatments: Deslorelin; Triptorelin Pamoate

Criteria

Inclusion Criteria: Patients undergoing ovarian stimulation for IVF using GnRH antagonist protocol

• Age < 40 years

• Anticipated high ovarian response

Exclusion Criteria:

• Endometriosis > than grade II

• One ovary